Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06129734 · ClinicalTrials.gov registry record · Phase 1

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

A Phase 1 study of Acute Myeloid Leukemia and Myeloid Malignancy, sponsored by Benjamin Tomlinson.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT06129734 is a Phase 1 study of Acute Myeloid Leukemia and Myeloid Malignancy that is actively recruiting participants, run by Benjamin Tomlinson. The registered enrollment target is 20 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06129734, a Phase 1 study of Acute Myeloid Leukemia and Myeloid Malignancy, is actively recruiting participants, sponsored by Benjamin Tomlinson.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants with acute myeloid leukemia and myelodysplastic syndromes. The main question it aims to answer is whether or not providing a new, gentler way of administering chemotherapy will help control leftover cancer with minimal side effects. This treatment involves decitabine and venetoclax. Participants will receive standard post-transplant care. Participants will be administered decitabine once per week with normal transplant follow up visits, and then will take a venetoclax pill about 6 to 8 hours later. Participants will meet their study team at the beginning, midway, and at the end of the trial to receive bone marrow testing. Participants will receive treatment until either one year of therapy, relapse, or recurrent dose limiting toxicity (DLT) despite dose reduction.

Conditions Studied

Acute Myeloid Leukemia Myeloid Malignancy

Interventions

  • DRUG Venetoclax
  • DRUG Decitabine

Study Locations (1)

Ohio

  • University Hospitals Seidman Cancer, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-07-28
Est. Completion 2027-07
Phase Phase 1

Sponsor

Benjamin Tomlinson

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06129734

The ClinicalTrials.gov registry entry for NCT06129734 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (83% lower). The listed sponsor is Benjamin Tomlinson, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.

NCT06129734 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT06129734 about?

NCT06129734 is a clinical study titled "Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant". The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants with acute myeloid leukemia and myelodysplastic syndromes. The main que...

What is the current status of trial NCT06129734?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-07-28. Estimated completion is 2027-07.

What conditions does trial NCT06129734 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myeloid Malignancy.

What interventions are being tested in trial NCT06129734?

The interventions under investigation include: Venetoclax (DRUG), Decitabine (DRUG).

Who is sponsoring clinical trial NCT06129734?

This trial is sponsored by Benjamin Tomlinson, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06129734 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myeloid Malignancy

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.